Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female participants older than 18 years~2. Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) prior to Day 1.~3. Evidence of pneumonia assessed by radiographic imaging (chest x-ray or chest CT scan).~4. Hospitalized for less than 72 hours and receiving supportive care for COVID-19~Exclusion Criteria:~1. Require non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) on Day 1 at the time of randomization~2. History of or known current thrombosis. Only if current thrombosis is suspected by the investigator, imaging testing is recommended (per local guidance) to exclude thrombosis.~3. Have a personal or first-degree family history of blood clotting disorders.~4. Participants who are immunocompromised, with known immunodeficiencies, or taking potent immunosuppressive agents (eg, azathioprine, cyclosporine).~5. Participants with any current malignancy or lymphoproliferative disorders that requires active treatment~6. Severe hepatic impairment, defined as Child-Pugh class C.~7. Severe anemia (hemoglobin \<8 g/dL).~8. Absolute lymphocyte count \<500 cells/mm;~9. Absolute neutrophil count \<1000 cells/mm.~10. Known allergy to tofacitinib.~11. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk associated with study participation or, in the investigator's judgment, make the participant inappropriate for the study.~12. Suspected or known active systemic bacterial, fungal, or viral infections (with the exception of COVID-19) including but not limited to: active herpes zoster infection; known active tuberculosis or history of inadequately treated tuberculosis; known B hepatitis, C hepatitis, or HIV.~13. Have received any of these within 4 weeks prior to the first dose of study intervention: any JAK inhibitors, potent immunosuppressants, or any biologic agents including IL-6 inhibitors (eg, tocilizumab) or IL-1 inhibitors (eg, anakinra) within the past 30 days; any potent cytochrome P450 inducer, such as rifampin, within the past 28 days or 5 half-lives, whichever is longer.~14. Have received estrogen-containing contraception or treatment with herbal supplements within 48 hours prior to the first dose of study intervention.~15. Have received treatment with corticosteroids equivalent to prednisone or methylprednisolone \>20 mg/day for equal or more than 14 consecutive days prior to screening.~16. Current participation in other trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): Tofacitinib 10mg twice daily for 14 days or until hospital discharge
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily for 14 days or until hospital discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete